builderall

January 9-10 | 2026

Hilton Aventura Miami
Aventura, FL

Conference Description

2026 Updates in Cancer Therapies (UCT): Moving Forward with a Review of the Latest Data is a comprehensive live CE event designed to deliver timely, practice-changing updates in oncology. This two-day in-person meetingheld January 9–10, 2026, at the Hilton Aventura Miami Hotel in Aventura, Florida, will feature expert-led sessions, panel discussions, and interactive Q&A segments.

UCT 2026 brings together leading oncology experts to deliver the most critical updates from ASCO, ESMO, and other major meetings, translating the latest data into practical, patient-centered care strategies. The agenda spans advances across lung, breast, prostate, and colorectal cancers, other solid tumors, and hematologic malignancies such aschronic lymphocytic leukemia, B-cell and T-cell non-Hodgkin lymphomas, and multiple myeloma. Sessions will also highlight emerging technologies such as circulating tumor DNA (ctDNA) and its integration into modern oncology practice.

Developed by an expert educational committee with input from past participant evaluations, UCT 2026 aims to foster critical thinking, enhance clinical decision-making, and promote multidisciplinary and interprofessional approaches to patient-centered cancer care.

Target Audience

This activity is intended for medical oncologists, radiation oncologists, surgical oncologists, oncology nurses, advanced practice providers (NPs, PAs), pharmacists, and other healthcare professionals involved in the care of patients with cancer.

Join us at UCT 2026 — for expert insights, cutting-edge data, and transformative updates in cancer care

Learner Objectives

Upon completion of this conference, participants will be able to:

  • Integrate novel frontline therapies for solid tumors and hematologic malignancies based on the latest regulatory approvals into clinical practice.

  • Utilize liquid biopsy and other novel diagnostic technologies to enhance cancer diagnosis, monitor response, and detect mechanisms of resistance.

  • Identify key oncogenic pathways and biomarkers to inform the development and selection of targeted therapeutic strategies.

  • Differentiate emerging immunotherapy approaches, including combination regimens with chemotherapy, radiotherapy, and biological agents, to optimize treatment outcomes.

  • Recognize and manage common adverse events associated with newly approved oncology therapies to improve patient safety and care.